Developer docs
API playgroundTry for free, no card

Search company profiles

4bases

Full company profile

uuid000otls

Namestring
4bases
Legal namestring
4bases SA
Websiteurl
4bases.ch
Company typeenum
Private
Founded yearint
2013
Descriptiontext

4bases SA is a privately held Swiss biotechnology company, founded in 2013 and headquartered at Tecnopolo Ticino in Manno, Switzerland, with a production facility in Italy. The company develops, manufactures, and commercializes clinically validated, CE-IVD certified reagent kits, bioinformatics software, and diagnostic protocols for platform-independent Next Generation Sequencing (NGS). Its product portfolio spans targeted gene panels covering cardiovascular disease (CARDIO pro), hematologic malignancies (HEMATO pro, 146 genes), hereditary and somatic cancer predisposition (HEVA Pro), chronic kidney disorders (NEPHRO pro, 92 genes), thalassemia, familial hypercholesterolemia, BRCA1/2 analysis (BRaCA), clinical exome (ClinEX Pro), and whole exome sequencing (WholEx pro). The portfolio is complemented by the 4eVar cloud-based data analysis platform and the KaryoSolver workflow, which combines KaryoPrep library preparation with real-time software for copy number variant detection on nanopore sequencing devices, and InnoGraft, an RUO platform for non-invasive dd-cfDNA-based monitoring of solid organ transplant recipients.

The company's business model combines one-time sales of CE-IVD reagent kits with recurring subscription elements for cloud-based data analysis software (4eVar, KaryoSolver). It operates a sales-led go-to-market targeting clinical laboratories, hospital diagnostic centers, and healthcare professionals across Europe, with distribution via direct sales, regional distributors, and technology partnerships such as the collaboration with Oxford Nanopore Technologies and Meridian Bioscience. Customers include academic and public hospitals conducting pilot validations (Careggi University Hospital in Florence and a public hospital in Vicenza for KaryoSolver). Strategic priorities are evident in three partnerships executed within three years, most recently the June 2026 Meridian Bioscience agreement to lyophilize KaryoSolver for ambient-temperature global distribution, and product expansion into transplant medicine via InnoGraft. The company remains founder-controlled under CEO Fabio Grandi and has not disclosed external institutional funding rounds.

Short descriptiontext

4bases SA is a Swiss CE-IVD NGS diagnostics company that develops and commercializes validated genetic reagent kits, bioinformatics software (4eVar), and diagnostic workflows for clinical laboratories and healthcare professionals across Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersManno, Switzerland
HQ citystring
Manno
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genetic diagnostic solutions, next generation sequencing kits, CE-IVD diagnostic reagents, clinical genomics software, cytogenetic analysis platforms
Industry6 codes
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Genetic Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1CE-IVD Reagent Kits
TypeOne Time License
Description

Sale of clinically validated diagnostic reagent kits for platform-independent New Generation DNA Sequencing (NGS)

4bases.ch
2Data Analysis Software
TypeSubscription Recurring
Description

Software tools including 4eVar cloud platform and KaryoSolver software for genetic data analysis

4bases.ch
3Diagnostic Kits
TypeOne Time License
Description

Commercialization of diagnostic kits including KaryoSolver for cytogenetics and InnoGraft for transplant monitoring

4bases.ch
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 12 records shown
1InnoGraft
Description

Non-invasive platform for longitudinal monitoring of solid organ transplant recipients, detecting donor-derived cell-free DNA (dd-cfDNA) in recipient's plasma.

4bases.ch
+11 more records
Core offering1 text field

4bases develops, produces, and commercializes CE-IVD certified diagnostic reagent kits for platform-independent Next Generation DNA Sequencing (NGS), alongside proprietary data analysis software and diagnostic protocols. Its portfolio includes targeted panels for cardiovascular, hematologic, oncologic, renal, and hereditary disease testing, as well as the KaryoSolver nanopore-based CNV detection workflow and the InnoGraft dd-cfDNA platform for transplant monitoring.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • KaryoSolver achieved 100% detection of known pathogenic/likely pathogenic variants in clinical validation study (509 samples)
+3 more records
Product overview1 text field

4bases offers a comprehensive portfolio of CE-IVD genetic diagnostic solutions for Next Generation Sequencing (NGS), comprising capture-based reagent kits, bioinformatics software platforms, and diagnostic workflows. The product lineup includes: CARDIO pro (cardiovascular disease panel), HEMATO pro (hematologic malignancies panel covering 146 genes), HEVA Pro (hereditary cancer predisposition panel with 43+ genes), NEPHRO pro (chronic kidney disease panel with 92 genes), THALASSEMIA panel, BRaCA (BRCA1/2 analysis), ClinEX Pro, and WholEx pro (whole exome sequencing). Supporting platforms include 4eVar (cloud-based data analysis) and the KaryoSolver workflow (nanopore-based CNV detection). InnoGraft is the company's newest RUO product for transplant rejection monitoring via dd-cfDNA analysis. Products are designed for platform-independent NGS and include both CE-IVD certified diagnostic kits and Research Use Only products.

Product and service13 records
1CARDIO pro
CategoryCE-IVD diagnostic kit
Description

CE-IVD capture-based diagnostic kit designed for the comprehensive genetic characterization of familial cardiovascular diseases. Identifies SNVs and CNVs in both somatic and germline samples. For clinical laboratories performing genetic cardiovascular testing.

2HEMATO pro
CategoryCE-IVD diagnostic kit
Description

CE-IVD kit for analysis of complex genomic variants associated with Lymphoid and Myeloid Diseases. Analyzes 146 genes frequently mutated in hematologic malignancies. Validated for germline and somatic analysis of SNVs, indels, CNVs and ITD.

3HEVA Pro
CategoryCE-IVD diagnostic kit
Description

Advanced targeted NGS capture panel for comprehensive analysis of genes associated with hereditary and somatic cancer predisposition. Includes all ESMO-recommended core genes plus 43 additional genes involved in hereditary cancer susceptibility.

4NEPHRO pro
CategoryCE-IVD diagnostic kit
Description

CE-IVD panel for the analysis of 92 genes associated with hereditary kidney disorders, including Chronic Kidney Disease.

5THALASSEMIA panel
CategoryCE-IVD diagnostic kit
Description

NGS medical device for molecular profiling of variants causing alpha and beta Thalassemia. Analyzes HBB, HBA1, HBA2, HBD, HBG1, HBG2, HS-40 and LCRB genes. Validated for germline analysis of SNPs and indels from blood samples.

6FH panel
CategoryDiagnostic kit
Description

Diagnostic solution for assessment of Familial Hypercholesterolemia. Includes LDLR, APOB, and PCSK9 genes plus 6 other genes associated with FH.

7BRaCA
CategoryCE-IVD diagnostic kit
Description

CE-IVD kit for analysis of BRCA1 and BRCA2 genes. Compatible with Oxford Nanopore Technologies devices. Demonstrated 100% concordance with gold-standard methods (short-read sequencing, MLPA, Sanger sequencing) in internal studies.

8ClinEX Pro
CategoryCE-IVD diagnostic kit
Description

CE-IVD panel compatible with Oxford Nanopore Technologies for comprehensive genetic profiling in genetically heterogeneous disorders.

9WholEx pro
CategoryDiagnostic kit
Description

Whole exome sequencing kit with coverage of over 99% of protein-coding genes, enabling identification of various pathologies including rare diseases.

10InnoGraft
CategoryRUO diagnostic platform
Description

Non-invasive platform for longitudinal monitoring of solid organ transplant recipients. Detects donor-derived cell-free DNA (dd-cfDNA) in recipient plasma using a proprietary panel of 94 highly polymorphic SNPs. Features AI-driven cloud analytics for rejection risk evaluation, delivering results within 24 hours. Protected by two patents.

11KaryoSolver
CategoryDiagnostic workflow platform
Description

Real-time workflow for copy number variant (CNV) detection based on nanopore sequencing. Consists of KaryoPrep library preparation and KaryoSolver software for real-time data analysis via the 4eVar cloud platform. Targets prenatal diagnostics and oncohematology applications.

124eVar
CategoryBioinformatics software
Description

Proprietary cloud-based platform for real-time data analysis. Performs bioinformatics analysis for variant detection and copy number variant (CNV) analysis in NGS workflows.

13Microbiology Kits
CategoryDiagnostic kit
Description

NGS kits for microbial genomics analysis, including integration with One Codex for end-to-end microbiome analysis solutions in the EU.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-10
Description

Collaboration focused on expanding global access to KaryoSolver through Meridian's advanced lyophilization expertise. Meridian enabled ambient-stable NGS workflows by stabilizing the library preparation components, eliminating cold-chain requirements and extending shelf life for simplified global distribution. The partnership combines 4bases' assay design with Meridian's reagent stabilization platform.

2Platomics
Strategic tierStrategicTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-02-25
Description

Strategic agreement with Platomics GmbH to facilitate laboratory regulatory documentation under EU In Vitro Diagnostic Regulation (IVDR). The PlatoX platform streamlines generation of documentation for laboratory workflows through automation, templates, and integrated guidance, helping 4bases customers navigate regulatory compliance.

4bases.ch
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-03-20
Description

Strategic collaboration to combine nanopore sequencing devices with 4bases kits for rapid, high-accuracy analyses in human and cancer genetics. Initial focus on same-day BRCA1 and BRCA2 analysis with 100% concordance to gold-standard methods. Enables decentralized, flexible sequencing scalability for clinical researchers in Italy and Switzerland.

4Alberto Magi (University of Florence)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Professor Alberto Magi (Professor of Bioengineering, University of Florence) on KaryoSolver development and pilot studies in Italian hospitals. Prof. Magi leads validation studies at Careggi University Hospital (Florence) and public hospital system in Vicenza, generating clinical evidence on reproducibility, turnaround time, and resolution.

4bases.ch
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1TATAA Biocenter
TypeEmerging player
Description

Sweden-based molecular diagnostics provider offering qPCR/NGS services and reagents for clinical and research applications. Comparable European molecular diagnostics focus with overlapping customer base, though smaller product portfolio than 4bases.

TypeDirect peer
Description

Swedish company developing CE-IVD diagnostic kits for hereditary diseases using NGS. Closest direct comparable — similar size, similar product focus on hereditary/cardiovascular/cancer panels, and similar platform-independent NGS strategy targeting clinical labs in Europe.

TypeBroad incumbent
Description

Swiss-founded health technology company offering a broader cloud-based genomics platform for molecular diagnostics across hereditary cancers, rare diseases, and oncology. Overlaps with 4bases on NGS-based diagnostic workflows but operates a software/data analytics business model at significantly larger scale.

TypeDirect peer
Description

UK-based developer of NGS library preparation and target enrichment reagents for clinical and research applications. Comparable in product category (NGS library prep/capture kits), size, and clinical lab customer focus.

TypeDirect peer
Description

Dutch molecular diagnostics company producing CE-IVD NGS reagent kits and library preparation solutions for hereditary and oncology applications. Similar scale, product mix (CE-IVD kits + bioinformatics), and European clinical lab customer base.

TypeBroad incumbent
Description

Major life sciences tools company with a dedicated molecular diagnostics division including NGS kits for hereditary disease (formerly Multiplicom, acquired 2016). Comparable product category and CE-IVD positioning but operates at vastly larger scale with broader portfolio.

TypeDirect peer
Description

US-based transplant diagnostics company commercializing donor-derived cell-free DNA (dd-cfDNA) tests such as AlloSure for graft rejection monitoring. Direct comparable for InnoGraft's transplant monitoring value proposition, though much larger and commercially established.

TypeBroad incumbent
Description

Eurofins division offering molecular and transplant diagnostics services including dd-cfDNA testing. Competes with InnoGraft in transplant monitoring while Eurofins' broader portfolio overlaps with 4bases' clinical lab offerings at much larger scale.

TypeDirect peer
Description

US-based molecular diagnostics company developing CE-IVD and LDT-grade NGS kits for oncology and genetic disease applications. Comparable in product mix (CE-IVD NGS kits), regulatory strategy, and clinical lab customer focus.

TypeOthers
Description

Sequencing platform partner and adjacent ecosystem participant. While not a direct competitor (they sell sequencers, 4bases sells kits), their expanding menu of clinical IVD assays and partnerships with other kit developers positions them as both an enabler and a potential competitive threat to 4bases' nanopore-based workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

4bases

Clinical Genetic Diagnostics4bases.ch

4bases SA is a Swiss CE-IVD NGS diagnostics company that develops and commercializes validated genetic reagent kits, bioinformatics software (4eVar), and diagnostic workflows for clinical laboratories and healthcare professionals across Europe.

What 4bases does

4bases SA is a privately held Swiss biotechnology company, founded in 2013 and headquartered at Tecnopolo Ticino in Manno, Switzerland, with a production facility in Italy. The company develops, manufactures, and commercializes clinically validated, CE-IVD certified reagent kits, bioinformatics software, and diagnostic protocols for platform-independent Next Generation Sequencing (NGS). Its product portfolio spans targeted gene panels covering cardiovascular disease (CARDIO pro), hematologic malignancies (HEMATO pro, 146 genes), hereditary and somatic cancer predisposition (HEVA Pro), chronic kidney disorders (NEPHRO pro, 92 genes), thalassemia, familial hypercholesterolemia, BRCA1/2 analysis (BRaCA), clinical exome (ClinEX Pro), and whole exome sequencing (WholEx pro). The portfolio is complemented by the 4eVar cloud-based data analysis platform and the KaryoSolver workflow, which combines KaryoPrep library preparation with real-time software for copy number variant detection on nanopore sequencing devices, and InnoGraft, an RUO platform for non-invasive dd-cfDNA-based monitoring of solid organ transplant recipients.

The company's business model combines one-time sales of CE-IVD reagent kits with recurring subscription elements for cloud-based data analysis software (4eVar, KaryoSolver). It operates a sales-led go-to-market targeting clinical laboratories, hospital diagnostic centers, and healthcare professionals across Europe, with distribution via direct sales, regional distributors, and technology partnerships such as the collaboration with Oxford Nanopore Technologies and Meridian Bioscience. Customers include academic and public hospitals conducting pilot validations (Careggi University Hospital in Florence and a public hospital in Vicenza for KaryoSolver). Strategic priorities are evident in three partnerships executed within three years, most recently the June 2026 Meridian Bioscience agreement to lyophilize KaryoSolver for ambient-temperature global distribution, and product expansion into transplant medicine via InnoGraft. The company remains founder-controlled under CEO Fabio Grandi and has not disclosed external institutional funding rounds.

4bases firmographics

Firmographics
Name
4bases
Legal name
4bases SA
Website
https://4bases.ch
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
4bases SA is a Swiss CE-IVD NGS diagnostics company that develops and commercializes validated genetic reagent kits, bioinformatics software (4eVar), and diagnostic workflows for clinical laboratories and healthcare professionals across Europe.
Ownership category
akta.pro rank

4bases industry classification

Industry
Product category
Clinical Genetic Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Genetic diagnostic solutions
  • Next generation sequencing kits
  • CE-IVD diagnostic reagents
  • Clinical genomics software
  • Cytogenetic analysis platforms

Where 4bases is headquartered

Location

Headquarters

HQ city
Manno
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

4bases business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. CE-IVD Reagent Kits: Sale of clinically validated diagnostic reagent kits for platform-independent New Generation DNA Sequencing (NGS)
  2. Data Analysis Software: Software tools including 4eVar cloud platform and KaryoSolver software for genetic data analysis
  3. Diagnostic Kits: Commercialization of diagnostic kits including KaryoSolver for cytogenetics and InnoGraft for transplant monitoring

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

4bases product offering

Product offering

Core offering

4bases develops, produces, and commercializes CE-IVD certified diagnostic reagent kits for platform-independent Next Generation DNA Sequencing (NGS), alongside proprietary data analysis software and diagnostic protocols. Its portfolio includes targeted panels for cardiovascular, hematologic, oncologic, renal, and hereditary disease testing, as well as the KaryoSolver nanopore-based CNV detection workflow and the InnoGraft dd-cfDNA platform for transplant monitoring.

Product overview

4bases offers a comprehensive portfolio of CE-IVD genetic diagnostic solutions for Next Generation Sequencing (NGS), comprising capture-based reagent kits, bioinformatics software platforms, and diagnostic workflows. The product lineup includes: CARDIO pro (cardiovascular disease panel), HEMATO pro (hematologic malignancies panel covering 146 genes), HEVA Pro (hereditary cancer predisposition panel with 43+ genes), NEPHRO pro (chronic kidney disease panel with 92 genes), THALASSEMIA panel, BRaCA (BRCA1/2 analysis), ClinEX Pro, and WholEx pro (whole exome sequencing). Supporting platforms include 4eVar (cloud-based data analysis) and the KaryoSolver workflow (nanopore-based CNV detection). InnoGraft is the company's newest RUO product for transplant rejection monitoring via dd-cfDNA analysis. Products are designed for platform-independent NGS and include both CE-IVD certified diagnostic kits and Research Use Only products.

Differentiator

Problem solved

Functional benefit

Brands

  • InnoGraft: Non-invasive platform for longitudinal monitoring of solid organ transplant recipients, detecting donor-derived cell-free DNA (dd-cfDNA) in recipient's plasma.
  • KaryoSolver
  • 4eVAR
  • CARDIO pro
  • HEVA pro
  • WholEX pro
  • NEPHRO pro
  • HEMATO pro
  • BRaCA
  • ClinEX Pro
  • THALASSEMIA panel
  • FH panel

Products and services

  • CARDIO pro CE-IVD capture-based diagnostic kit designed for the comprehensive genetic characterization of familial cardiovascular diseases. Identifies SNVs and CNVs in both somatic and germline samples. For clinical laboratories performing genetic cardiovascular testing.
  • HEMATO pro CE-IVD kit for analysis of complex genomic variants associated with Lymphoid and Myeloid Diseases. Analyzes 146 genes frequently mutated in hematologic malignancies. Validated for germline and somatic analysis of SNVs, indels, CNVs and ITD.
  • HEVA Pro Advanced targeted NGS capture panel for comprehensive analysis of genes associated with hereditary and somatic cancer predisposition. Includes all ESMO-recommended core genes plus 43 additional genes involved in hereditary cancer susceptibility.
  • NEPHRO pro CE-IVD panel for the analysis of 92 genes associated with hereditary kidney disorders, including Chronic Kidney Disease.
  • THALASSEMIA panel NGS medical device for molecular profiling of variants causing alpha and beta Thalassemia. Analyzes HBB, HBA1, HBA2, HBD, HBG1, HBG2, HS-40 and LCRB genes. Validated for germline analysis of SNPs and indels from blood samples.
  • FH panel Diagnostic solution for assessment of Familial Hypercholesterolemia. Includes LDLR, APOB, and PCSK9 genes plus 6 other genes associated with FH.
  • BRaCA CE-IVD kit for analysis of BRCA1 and BRCA2 genes. Compatible with Oxford Nanopore Technologies devices. Demonstrated 100% concordance with gold-standard methods (short-read sequencing, MLPA, Sanger sequencing) in internal studies.
  • ClinEX Pro CE-IVD panel compatible with Oxford Nanopore Technologies for comprehensive genetic profiling in genetically heterogeneous disorders.
  • WholEx pro Whole exome sequencing kit with coverage of over 99% of protein-coding genes, enabling identification of various pathologies including rare diseases.
  • InnoGraft Non-invasive platform for longitudinal monitoring of solid organ transplant recipients. Detects donor-derived cell-free DNA (dd-cfDNA) in recipient plasma using a proprietary panel of 94 highly polymorphic SNPs. Features AI-driven cloud analytics for rejection risk evaluation, delivering results within 24 hours. Protected by two patents.
  • KaryoSolver Real-time workflow for copy number variant (CNV) detection based on nanopore sequencing. Consists of KaryoPrep library preparation and KaryoSolver software for real-time data analysis via the 4eVar cloud platform. Targets prenatal diagnostics and oncohematology applications.
  • 4eVar Proprietary cloud-based platform for real-time data analysis. Performs bioinformatics analysis for variant detection and copy number variant (CNV) analysis in NGS workflows.
  • Microbiology Kits NGS kits for microbial genomics analysis, including integration with One Codex for end-to-end microbiome analysis solutions in the EU.

Quantifiable outcome

  • KaryoSolver achieved 100% detection of known pathogenic/likely pathogenic variants in clinical validation study (509 samples)
  • +3 more outcomes

Companies that use 4bases

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

4bases technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature4 records

4bases partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and strategic.

  • Meridian BiosciencecoreTechnology or Integration · 10 June 2026Collaboration focused on expanding global access to KaryoSolver through Meridian's advanced lyophilization expertise. Meridian enabled ambient-stable NGS workflows by stabilizing the library preparation components, eliminating cold-chain requirements and extending shelf life for simplified global distribution. The partnership combines 4bases' assay design with Meridian's reagent stabilization platform.
  • PlatomicsstrategicImplementation/ SI/ Consulting Partner · 25 February 2025Strategic agreement with Platomics GmbH to facilitate laboratory regulatory documentation under EU In Vitro Diagnostic Regulation (IVDR). The PlatoX platform streamlines generation of documentation for laboratory workflows through automation, templates, and integrated guidance, helping 4bases customers navigate regulatory compliance.
  • Oxford Nanopore TechnologiescoreTechnology or Integration · 20 March 2023Strategic collaboration to combine nanopore sequencing devices with 4bases kits for rapid, high-accuracy analyses in human and cancer genetics. Initial focus on same-day BRCA1 and BRCA2 analysis with 100% concordance to gold-standard methods. Enables decentralized, flexible sequencing scalability for clinical researchers in Italy and Switzerland.
  • Alberto Magi (University of Florence)coreStrategic or Co-development PartnerCollaboration with Professor Alberto Magi (Professor of Bioengineering, University of Florence) on KaryoSolver development and pilot studies in Italian hospitals. Prof. Magi leads validation studies at Careggi University Hospital (Florence) and public hospital system in Vicenza, generating clinical evidence on reproducibility, turnaround time, and resolution.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

4bases competitors and assessment

Company assessment

Emerging players

  • TATAA Biocenter: Sweden-based molecular diagnostics provider offering qPCR/NGS services and reagents for clinical and research applications. Comparable European molecular diagnostics focus with overlapping customer base, though smaller product portfolio than 4bases.

Direct peers

  • Devyser: Swedish company developing CE-IVD diagnostic kits for hereditary diseases using NGS. Closest direct comparable — similar size, similar product focus on hereditary/cardiovascular/cancer panels, and similar platform-independent NGS strategy targeting clinical labs in Europe.
  • Nonacus: UK-based developer of NGS library preparation and target enrichment reagents for clinical and research applications. Comparable in product category (NGS library prep/capture kits), size, and clinical lab customer focus.
  • NimaGen: Dutch molecular diagnostics company producing CE-IVD NGS reagent kits and library preparation solutions for hereditary and oncology applications. Similar scale, product mix (CE-IVD kits + bioinformatics), and European clinical lab customer base.
  • CareDx: US-based transplant diagnostics company commercializing donor-derived cell-free DNA (dd-cfDNA) tests such as AlloSure for graft rejection monitoring. Direct comparable for InnoGraft's transplant monitoring value proposition, though much larger and commercially established.
  • Asuragen: US-based molecular diagnostics company developing CE-IVD and LDT-grade NGS kits for oncology and genetic disease applications. Comparable in product mix (CE-IVD NGS kits), regulatory strategy, and clinical lab customer focus.

Broad incumbents

  • SOPHiA Genetics: Swiss-founded health technology company offering a broader cloud-based genomics platform for molecular diagnostics across hereditary cancers, rare diseases, and oncology. Overlaps with 4bases on NGS-based diagnostic workflows but operates a software/data analytics business model at significantly larger scale.
  • Agilent Technologies (Resolution Bioscience / Multiplicom): Major life sciences tools company with a dedicated molecular diagnostics division including NGS kits for hereditary disease (formerly Multiplicom, acquired 2016). Comparable product category and CE-IVD positioning but operates at vastly larger scale with broader portfolio.
  • Eurofins Genoma / Eurofins Transplant Genomics: Eurofins division offering molecular and transplant diagnostics services including dd-cfDNA testing. Competes with InnoGraft in transplant monitoring while Eurofins' broader portfolio overlaps with 4bases' clinical lab offerings at much larger scale.

Others

  • Oxford Nanopore Technologies: Sequencing platform partner and adjacent ecosystem participant. While not a direct competitor (they sell sequencers, 4bases sells kits), their expanding menu of clinical IVD assays and partnerships with other kit developers positions them as both an enabler and a potential competitive threat to 4bases' nanopore-based workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

4bases social profiles

Digital presence

4bases compliance and trust

Trust signal

Compliance2 records

4bases financial estimates

Financial estimate

Revenue estimate

Valuation estimate

4bases leadership team

Management profile

Number of profiles

Profiles1 record

4bases funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

4bases M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 4bases

What does 4bases do?

4bases develops, produces, and commercializes CE-IVD certified diagnostic reagent kits for platform-independent Next Generation DNA Sequencing (NGS), alongside proprietary data analysis software and diagnostic protocols. Its portfolio includes targeted panels for cardiovascular, hematologic, oncologic, renal, and hereditary disease testing, as well as the KaryoSolver nanopore-based CNV detection workflow and the InnoGraft dd-cfDNA platform for transplant monitoring.

Is 4bases a public or private company?

4bases is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was 4bases founded?

4bases was founded in 2013. It employs 11 to 50 people.

Where is 4bases based?

4bases is headquartered in Manno, Switzerland, in the Europe region.

How does 4bases make money?

Three revenue lines are on record. CE-IVD Reagent Kits are the primary driver. The others are data Analysis Software and diagnostic Kits.

Who are 4bases's main competitors?

TATAA Biocenter is listed as an emerging player. Direct peers are Devyser, Nonacus, NimaGen, CareDx and Asuragen. Broad incumbents are SOPHiA Genetics, Agilent Technologies (Resolution Bioscience / Multiplicom) and Eurofins Genoma / Eurofins Transplant Genomics. Oxford Nanopore Technologies is listed as an others.

Does 4bases have an API?

No public API is recorded for 4bases.

What industry is 4bases in?

4bases's product category is Clinical Genetic Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals